Crohn's disease: beyond antagonists of tumour necrosis factor

The Lancet

Volumn 372, Issue 9632, 2008, Pages 67-81

  Peyrin Biroulet, Laurent ^a   Desreumaux, Pierre ^a   Sandborn, William J ^b   Colombel, Jean Frédéric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABT 874; ALICAFORSEN; AMG 714; ATLIZUMAB; C 326; CELL ADHESION MOLECULE; CH 5D12; CNTO 1275; COX 282B; CYTOKINE; DORAMAPIMOD; FONTOLIZUMAB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HUMAN GROWTH HORMONE; INTERLEUKIN 10; INTERLEUKIN 18 BINDING PROTEIN; IPL 42; J 695; LENALIDOMIDE; MDX 1100; MLN 0002; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 4; OPEBACAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; SEMAPIMOD; STA 53226; TEDUGLUTIDE; THALIDOMIDE; THYMOSIN BETA4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VISILIZUMAB; VT 214; VT 346;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BASAL CELL CARCINOMA; BONE PAIN; CHILL; CLINICAL TRIAL; COLON PERFORATION; COMMON COLD; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPEREOSINOPHILIA; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INJECTION SITE REACTION; INNATE IMMUNITY; INSOMNIA; INTESTINE EPITHELIUM; KIDNEY CARCINOMA; LYMPHOCYTE; MYALGIA; NAUSEA; NEURILEMOMA; NEUROPATHY; NONHUMAN; PARALYTIC ILEUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETCHING; REVIEW; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SORE THROAT; SYNDROME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

EID: 46149125761     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60995-2     Document Type: Review

References (121)

1. Bamias G., Nyce M., De La Rue S., and Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 143 (2005) 895-904
2. Baumgart D., and Carding S. Inflammatory bowel disease: cause and immunobiology. Lancet 369 (2007) 1627-1640
3. Cho J., and Weaver C. The genetics of inflammatory bowel disease. Gastroenterology 133 (2007) 1327-1339
4. Xavier R., and Podolsky D. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434
5. Tamboli C., Neut C., Desreumaux P., and Colombel J. Dysbiosis as a prerequisite for IBD. Gut 53 (2004) 1057
6. Barnich N., Carvalho F., Glasser A., et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 117 (2007) 1566-1574
7. Abraham C., and Cho J. Bugging of the intestinal mucosa. N Engl J Med 357 (2007) 708-710
8. Turnbaugh P., Ley R., Hamady M., Fraser-Liggett C., Knight R., and Gordon J. The human microbiome project. Nature 449 (2007) 804-810
9. Buhner S., Buning C., Genschel J., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 55 (2006) 342-347
10. Hugot J., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
11. Ogura Y., Bonen D., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
12. Wehkamp J., Salzman N., Porter E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 102 (2005) 18129-18134
13. Duerr R., Taylor K., Brant S., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
14. Targan S., Hanauer S., van Deventer S., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
15. Hanauer S., Feagan B., Lichtenstein G., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
16. Lemann M., Mary J., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
17. Present D., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
18. Sands B., Anderson F., Bernstein C., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
19. Hanauer S., Sandborn W., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
20. Colombel J., Sandborn W., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
21. Sandborn W., Feagan B., Stoinov S., et al., PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
22. Sandborn W., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
23. Korzenik J., and Podolsky D. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5 (2006) 197-209
24. Canva-Delcambre V., Jacquot S., et al. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 10 (1996) 721-727
25. Stronkhorst A., Radema S., Yong S., et al. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 40 (1997) 320-327
26. Hommes D., Targan S., Baumgart D., Dignass A., Mayer L., and Lowder J. A phase I study: visilizumab therapy in Crohn's disease (CD) patients refractory to infliximab treatment. Gastroenterology 130 suppl 2 (2006) A111
27. Lowder J., Baumgart D., Hommes D., et al. A phase I study: visilizumab therapy in Crohn's disease (CD) patients with perianal fistula. Gut 55 suppl (2006) A127
28. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996 discussion 947.
29. Hommes D., Mikhajlova T., Stoinov S., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1131-1137
30. Reinisch W., Hommes D., Van Assche G., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1138-1144
31. Dumont F. Fontolizumab protein design labs. Curr Opin Investig Drugs 6 (2005) 537-544
32. Mannon P., Fuss I., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
33. Sandborn W., Feagan B., Fedorak R., et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology 132 suppl 2 (2007) A51
34. Burakoff R., Barish C., Riff D., et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 12 (2006) 558-565
35. Kasran A., Boon L., Wortel C., et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 22 (2005) 111-122
36. Oyama Y., Craig R., Traynor A., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128 (2005) 552-563
37. Dotan I., Van der Woude J., Schreiber S., Plasse T., and Powers B. A randomized, double blind, placebocontrolled phase II study with long-term open-label extension of semapimod (CNI-1493) for treatment of moderate to severe Crohn's disease. Gut 55 suppl (2006) A22
38. Hommes D., van den Blink B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 (2002) 7-14
39. Schreiber S., Feagan B., D'Haens G., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 325-334
40. Plamondon S., Ng S., and Kamm M. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 25 (2007) 557-567
41. Fedorak R., Gangl A., Elson C., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119 (2000) 1473-1482
42. Schreiber S., Fedorak R., Nielsen O., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119 (2000) 1461-1472
43. Colombel J., Rutgeerts P., Malchow H., et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49 (2001) 42-46
44. Sands B., Bank S., Sninsky C., et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117 (1999) 58-64
45. Sands B., Winston B., Salzberg B., et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16 (2002) 399-406
46. Herrlinger K., Witthoeft T., Raedler A., et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 101 (2006) 793-797
47. Braat H., Rottiers P., Hommes D., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 754-759
48. Gordon F., Lai C., Hamilton M., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121 (2001) 268-274
49. Ghosh S., Goldin E., Gordon F., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
50. Sands B., Kozarek R., Spainhour J., et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13 (2007) 2-11
51. Sandborn W., Colombel J., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
52. Targan S., Feagan B., Fedorak R., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132 (2007) 1672-1683
53. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
54. Kleinschmidt-DeMasters B., and Tyler K. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
55. Langer-Gould A., Atlas S., Green A., Bollen A., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
56. Yousry T., Major E., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
57. Yacyshyn B., Bowen-Yacyshyn M., Jewell L., et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114 (1998) 1133-1142
58. Schreiber S., Nikolaus S., Malchow H., et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120 (2001) 1339-1346
59. Yacyshyn B., Chey W., Goff J., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51 (2002) 30-36
60. Yacyshyn B., Barish C., Goff J., et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 16 (2002) 1761-1770
61. Yacyshyn B., Schievella A., Sewell K., and Tami J. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. Clin Exp Immunol 141 (2005) 141-147
62. Yacyshyn B., Chey W., Wedel M., Yu R., Paul D., and Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5 (2007) 215-220
63. Keshav S., Ungashe S., Zheng W., Bekker P., Wright K., and Schall T. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease. Gastroenterology 132 suppl 2 (2007) A157
64. Bekker P., Schreiber S., Keshav S., et al. PROTECT-1, prospective randomized oral therapy evaluationof CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 56 suppl (2007) A23
65. Feagan B., Greenberg G., Wild G., et al. Efficacy and safety of a humanized a4ß7 antibody in active Crohn's disease (CD). Gastroenterology 124 (2003) A25-A26
66. Buchman A., Katz S., Shnaidman M., and Jacobs D. Effect of teduglutide on patients with moderate-severe Crohn's disease after 8 weeks of therapy: a prospective, double-blind, placebo-controlled trial. Gastroenterology 131 (2006) 949-951
67. Slonim A., Bulone L., Damore M., Goldberg T., Wingertzahn M., and McKinley M. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 342 (2000) 1633-1637
68. Dieckgraefe B., and Korzenik J. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360 (2002) 1478-1480
69. Korzenik J., Dieckgraefe B., Valentine J., Hausman D., and Gilbert M. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005) 2193-2201
70. Valentine J., Fedorak R., Fredlund P., and Feagan B. Sargramostim induces steroid-free remission in corticosteroid-dependent Crohn's Disease: results of n.o.v.e.l. 2, a phase II multicenter study. Gastroenterology 132 Suppl 2 (2007) A502
71. Feagan B., Anderson F., Radford-Smith G., Solovyov O., and Zurdel-Dillinger S. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of n.o.v.e.l. 4, a Phase III multicenter study. Gastroenterology 132 suppl 2 (2007) A103
72. Korzenik J., and Dieckgraefe B. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 21 (2005) 391-400
73. Margalit M., Israeli E., Shibolet O., et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 101 (2006) 561-568
74. Pizarro T., and Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med 58 (2007) 433-444
75. Carpenter P., Appelbaum F., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
76. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
77. Mitsuyama K., Toyonaga A., Sasaki E., et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36 (1995) 45-49
78. Krueger G., Langley R., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
79. Vincenti F., and Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Ann Rev Med 58 (2007) 347-358
80. Lopez-Cubero S., Sullivan K., and McDonald G. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 114 (1998) 433-440
81. Snowden J., Passweg J., Moore J., et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 31 (2004) 482-488
82. Travis S., Yap L., Hawkey C., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11 (2005) 713-719
83. Hynes R. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
84. Bevilacqua M. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 11 (1993) 767-804
85. Olaussen R., Karlsson M., Lundin K., Jahnsen J., Brandtzaeg P., and Farstad I. Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation. Gastroenterology 132 (2007) 2371-2382
86. Suzuki Y., Yoshimura N., Saniabadi A., and Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49 (2004) 565-571
87. Wallis K., Walters J., and Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther 25 (2007) 365-372
88. Wang X., Wang B., Wu J., and Wang G. Beneficial effects of growth hormone on bacterial translocation during the course of acute necrotizing pancreatitis in rats. Pancreas 23 (2001) 148-156
89. Huang Y., Wang S., Yi C., Ying M., Lin Y., and Zhi M. Effects of recombinant human growth hormone on rat septic shock with intraabdominal infection by E. coli. World J Gastroenterol 8 (2002) 1134-1137
90. Shulman D. Gastrointestinal effects of growth hormone. Endocrine 12 (2000) 147-152
91. Decker D., Springer W., Tolba R., Lauschke H., Hirner A., and von Ruecker A. Perioperative treatment with human growth hormone down-regulates apoptosis and increases superoxide production in PMN from patients undergoing infrarenal abdominal aortic aneurysm repair. Growth Horm IGF Res 15 (2005) 193-199
92. Hyun J., and Barrett T. Oral tolerance therapy in inflammatory bowel disease. Am J Gastroenterol 101 (2006) 569-571
93. Macpherson A., Khoo U., Forgacs I., Philpott-Howard J., and Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38 (1996) 365-375
94. Neurath M., Fuss I., Kelsall B., Presky D., Waegell W., and Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 183 (1996) 2605-2616
95. Plevy S., Salzberg B., Van Assche G., et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133 (2007) 1414-1422
96. PDL BioPharma news release. PDL BioPharma announces significant strategic and portfolio changes to focus on antibody discovery and development (Aug 28, 2007). http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-newsArticl e&ID=1045731&highlight (accessed April 1, 2008).
97. Van Assche G., Dalle I., Noman M., et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 98 (2003) 369-376
98. Van Assche G., Sandborn W., Feagan B., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55 (2006) 1568-1574
99. Creed T., Norman M., Probert C., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18 (2003) 65-75
100. Creed T., Probert C., Norman M., et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 23 (2006) 1435-1442
101. Kremer J., Genant H., Moreland L., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006) 865-876
102. Genovese M., Becker J., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
103. Smolen J., Aletaha D., Koeller M., Weisman M., and Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
104. Maini R., Taylor P., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
105. Sands B., Sandborn W., Wolf D., et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 40 (2006) 482-489
106. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology (in press).
107. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in Crohn's disease patients treated with immunosuppression: can we screen for elevated risk of PML? Gut (in press).
108. Thulesen J., Hartmann B., Hare K., et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53 (2004) 1145-1150
109. Salmi M., and Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 108 (2006) 1555-1561
110. Silverman J., Liu Q., Bakker A., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23 (2005) 1556-1561
111. Jeong K., Mabry R., and Georgiou G. Avimers hold their own. Nat Biotechnol 23 (2005) 1493-1494
112. Di Marzo V., and Izzo A. Endocannabinoid overactivity and intestinal inflammation. Gut 55 (2006) 1373-1376
113. Garcia-Olmo D., Garcia-Arranz M., Herreros D., Pascual I., Peiro C., and Rodriguez-Montes J. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48 (2005) 1416-1423
114. Van Gossum A., Dewit O., Louis E., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 13 (2007) 135-142
115. Rolfe V., Fortun P., Hawkey C., and Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2006) CD004826.
116. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
117. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
118. Rutgeerts P., Vermeire S., and Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 56 (2007) 453-455
119. Rosh J., and Oliva-Hemker M. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr 44 (2007) 165-167
120. Hanauer S. Safety first: messages from Digestive Disease Week 2006. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 415
121. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J., and Cosnes J. Predictors of Crohn's disease. Gastroenterology 130 (2006) 650-656